Susquehanna International Group, LLP Atreca, Inc. Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.13 - $0.38 $13,612 - $39,790	104,712 New	104,712 $13,000
Q2 2022 Aug 15, 2022	BUY	$1.56 - $3.25 $11,765 - $24,511	7,542 Added 20.17%	44,926 $80,000
Q1 2022 May 16, 2022	SELL	$1.61 - $5.2 $27,036 - $87,323	-16,793 Reduced 31.0%	37,384 $119,000
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $103,064 - $225,880	35,911 Added 196.6%	54,177 $164,000
Q3 2021 Nov 15, 2021	SELL	$4.91 - $9.07 $371,878 - $686,952	-75,739 Reduced 80.57%	18,266 $114,000
Q2 2021 Aug 11, 2021	BUY	$7.82 - $13.8 $396,982 - $700,557	50,765 Added 117.4%	94,005 $801,000
Q1 2021 May 17, 2021	BUY	$13.0 - $19.34 $326,742 - $486,091	25,134 Added 138.82%	43,240 $663,000
Q4 2020 Feb 16, 2021	BUY	$13.03 - $17.09 $235,921 - $309,431	18,106 New	18,106 $292,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.